Clinical trials: in Ukraine
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Pemphigus
A Study of PRN1008 in Patients With Pemphigus
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment [BT] period) followed by an open-label extension [OLE] period intended to evaluate the efficacy and safety of oral PRN1008…
- Trial name
- NCT03762265
- Testing
- Rilzabrutinib
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 131 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Ulcerative Colitis
A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)
A 2-part study, comprising of a 36-week placebo-controlled period (PCP) and a 24-week open-label extension (OLE) period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to background UC therapy of…
- Trial name
- NCT04556383
- Testing
- GB004
- Where
- 77 sites in United States, Georgia and 7 more
- Volunteers
- 236 people
- Sponsor
- GB004, Inc.
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Spondyloarthritis
Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
The purpose of this study is to evaluate the effect of treatment withdrawal compared to continued treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence of a "flare" in non-radiographic axial…
- Trial name
- NCT03253796
- Testing
- Golimumab
- Where
- 71 sites in Czechia, Germany and 7 more
- Volunteers
- 323 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Pain
Peculiarities of Pain in Patients With Mine-explosive Wounds Depending on the Localization of the Wound at the Stages of Treatment
Mine-explosive wounds in the general structure of combat sanitary losses reach 25%. They are characterized by significant damage resulting in high intensity pain.
- Trial name
- PPPM-EWDL (NCT05485285)
- Testing
- visual analog scale
- Where
- Ukraine
- Volunteers
- 660 people
- Sponsor
- Bogomolets National Medical University
Primary Immune Thrombocytopenia
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.
- Trial name
- NCT03102593
- Testing
- ARGX-113
- Where
- 30 sites in Austria, Belgium and 8 more
- Volunteers
- 38 people
- Sponsor
- argenx
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Epidermolysis Bullosa
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
This was a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB). EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response…
- Trial name
- EASE (NCT03068780)
- Testing
- Oleogel-S10, Control gel
- Where
- 51 sites in United States, Argentina and 24 more
- Volunteers
- 223 people
- Sponsor
- Amryt Research Limited
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with…
- Conditions
- Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT02825836
- Testing
- TL-895, Navtemadlin
- Where
- 17 sites in United States, Hungary and 5 more
- Volunteers
- 130 people
- Sponsor
- Telios Pharma, Inc.
Regurgitation, Gastric, Diarrhea
To Assess the Safety and Tolerance of Infant Formula With Locust Bean Gum in Infants With Regurgitation
A randomized, controlled study to evaluate the safety and tolerance of an infant formula with locust bean gum in infants with regurgitation. (Solar)
- Trial name
- Solar (NCT04042454)
- Testing
- milk based anti-regurgitation infant formula, Milk based infant formula
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
The objectives of Period 1 were the following: To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly…
- Trial name
- SELECT-EARLY (NCT02706873)
- Testing
- Methotrexate, Upadacitinib
- Where
- 290 sites in United States, Argentina and 43 more
- Volunteers
- 1,002 people
- Sponsor
- AbbVie
Plaque Psoriasis
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and…
- Trial name
- NCT03992261
- Testing
- Halobetasol Topical Foam
- Where
- 11 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Mayne Pharma International Pty Ltd
Lung Infection, Pneumonia, Ventilator-Associated
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S.
- Conditions
- Lung Infection, Pneumonia, Ventilator-Associated, Infection, Bacterial, Staphylococcus Aureus
- Trial name
- AR-301-002 (NCT03816956)
- Testing
- AR-301
- Where
- 45 sites in Belarus, Belgium and 13 more
- Volunteers
- 174 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
COVID-19
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
- Trial name
- TACKLE (NCT04723394)
- Testing
- AZD7442
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 910 people
- Sponsor
- AstraZeneca
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks.
- Trial name
- Antelope (NCT04115488)
- Testing
- Intravenous (IV) infusions
- Where
- 48 sites in Belarus, Croatia and 5 more
- Volunteers
- 265 people
- Sponsor
- Polpharma Biologics S.A.
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer